Delving into the Latest Updates on Engineered skin substitute(Lonza Group AG) with Synapse

Overview

Basic Info

Drug Type

Biological products

Synonyms

Cultured skin substitute, ESS-W, Engineered skin substitute

+ [2]

Target-

Action-

Mechanism-

Therapeutic Areas

Other Diseases

Active Indication-

Inactive Indication

Burns

Originator Organization

Lonza Group AG

Active Organization-

Inactive Organization

Amarantus Bioscience Holdings, Inc.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this research study is to test how well the investigational treatment, Engineered Skin Substitutes (ESS-W), works for covering and treating burn wounds.
The areas of the body that are treated with ESS-W will be compared to similar areas treated with the patient's own skin (split-thickness skin autograft (AG)). A skin autograft (AG) will be performed by taking healthy skin from one area of the body and placing it on the burned area.

Start Date01 Sep 2016

Sponsor / Collaborator

Amarantus Bioscience Holdings, Inc.

[+1]

100 Clinical Results associated with Engineered skin substitute(Lonza Group AG)

Login to view more data

100 Translational Medicine associated with Engineered skin substitute(Lonza Group AG)

Login to view more data

100 Patents (Medical) associated with Engineered skin substitute(Lonza Group AG)

Login to view more data

100 Deals associated with Engineered skin substitute(Lonza Group AG)

Login to view more data